Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization
Vascular Medicine · 2026
DOI: 10.1177/1358863x251405282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Medicine, 2026. Verfasst von Hyungseop Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, R…. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Plaque, Atherosclerotic, Neovascularization, Pathologic, Ezetimibe. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Background
Intraplaque neovascularization (IPN) is related to the progression of atherosclerotic plaque. The impact of lipid-lowering therapy (LLT) on IPN regression is unclear. We aimed to investigate the efficacy of LLT to regress IPN.
Methods
Between April 2022 and July 2024, 56 patients who had percutaneous coronary intervention (PCI) for angina or acute coronary syndrome and had not used LLT for at least 6 months were included. Contrast-enhanced ultrasound (CEUS) of the carotid artery was performed to evaluate IPN and intima–media thickness (IMT) within 7 days post-PCI. They received a combination of rosuvastatin 10 mg and ezetimibe 10 mg starting after PCI and continued for 1 year. Lipid profile changes and contrast enhancement were evaluated at baseline and 1 year later. The primary outcome was IPN regression, defined as the downgrade changes in the enhancement of contrast in atherosclerotic plaque at follow up.
Results
The mean follow up was 12.6 ± 0.9 months. The IPN regression rate was 41%. Patients achieving IPN regression initially had a higher low-density lipoprotein-cholesterol (LDL-C) level and a greater percentage reduction in LDL-C. Whereas lipid profiles change significantly, no notable alterations were observed in IMT, plaque thickness, or plaque density. However, a 59% reduction in LDL-C was identified as the optimal cutoff level for IPN regression (OR 0.86, 95% CI 0.75–0.96).
Conclusion
LLT, such as rosuvastatin 10 mg with ezetimibe 10 mg, may effectively inhibit IPN by reducing LDL-C levels, providing a promising treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Cardiology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.
ORCID-Profile: Hyungseop Kim
Zitieren
APA
Kim, H., Lee, H. J., Kim, I. C., Cho, Y. K., & Lee, C. H. (2026). Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization. Vascular Medicine. https://doi.org/10.1177/1358863x251405282
Vancouver
Kim H, Lee HJ, Kim IC, Cho YK, Lee CH. Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization. Vascular Medicine. 2026. doi:10.1177/1358863x251405282
BibTeX
@article{Kim2026,
author = {Kim, Hyungseop and Lee, Hee-Jeong and Kim, In-Cheol and Cho, Yun-Kyeong and Lee, Cheol-Hyun},
title = {Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization},
journal = {Vascular Medicine},
year = {2026},
doi = {10.1177/1358863x251405282}
}
EUVIMED